Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans

Hallschmid M., Randeva H., Tan BK., Kern W., Lehnert H.

Laboratory Study with a reported sample of 38 on Type 2 Diabetes, published in Diabetes (2009) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Diabetes (2009)
Reported sample size
38
Source database
Europe PMC
PMID
19095760
PMCID
PMC2646062
DOI
10.2337/db08-1176
Citations
49

Abstract (original English)

Objective Observations of elevated circulating concentrations of visfatin (PBEF/Nampt) in obesity and diabetes suggest that this recently described adipokine is involved in the regulation of body weight and metabolism. We examined in humans whether visfatin is found in cerebrospinal fluid (CSF) and, if so, how CSF visfatin concentrations relate to adiposity and metabolic parameters. Research design and methods We measured visfatin concentrations in the plasma and CSF of 38 subjects (18 men and 20 women; age 19-80 years) with a wide range of body weight (BMI 16.24-38.10 kg/m2). In addition, anthropometric parameters and endocrine markers were assessed. Bivariate correlation coefficients were determined and stepwise multiple regression analyses were performed to detect associations of CSF and plasma visfatin levels with relevant parameters. Results Plasma visfatin levels increased with rising BMI (P 0.13) nor CSF (P > 0.61) visfatin concentrations differed between men and women. Conclusions Our data indicate that visfatin concentrations in human CSF decrease with rising body fat, supporting the assumption that visfatin transport across the blood-brain barrier is impaired in obesity and that central nervous visfatin insufficiency or resistance are linked to pathogenetic mechanisms of obesity.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueHumansDiabetes MellitusInsulin ResistanceObesityBody Mass IndexWaist-Hip RatioRegression AnalysisSex CharacteristicsAdult

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research